3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh

A compound of formula (I)

• wherein:
• R1 and R2 are each independently hydrogen, deuterium, halo, hydroxyl, NH2, aryl, heteroaryl, or optionally substituted C1-4 alkyl,
• wherein said C1-4 alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of:
• halo, hydroxyl, and NH2;
• R3a is hydrogen, deuterium, C1-6 alkyl, phenyl, or benzyl and
• R3b is hydrogen, deuterium, or C1-6 alkyl;
• or
• R3a and R3b are joined together forming an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocyclic ring,
• wherein said cycloalkyl and heterocyclic rings are each optionally substituted with one or two substituents each independently selected from the group consisting of:
• halo, hydroxyl, oxo, NH2, and C1-3 alkyl;
• R4a is hydrogen, C1-6 alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted heteroaryl, or methylene-dibenzene,
• wherein said phenyl, benzyl, and heteroaryl rings are optionally substituted with one to three substituents each independently selected from the group consisting of:
• halo, hydroxyl, cyano, nitro, C1-4 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, C1-6 alkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, phenoxy, —COORb, —SO2Rb, —NHC(O)Rb, and —NRbRb and
• R4b is hydrogen, deuterium, or C1-3 alkyl;
• or
• R4a and R4b are joined together forming an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocyclic ring,
• wherein said cycloalkyl and heterocyclic rings are optionally substituted with one or two substituents each independently selected from the group consisting of:
• halo, hydroxyl, oxo, NH2, and C1-3 alkyl,
• provided that only one of R3a and R3b and R4a and R4b are joined together forming a ring;
• R5a is hydrogen or deuterium;
• R5b is hydrogen, deuterium, methyl, ethyl, CD3, CF3, CH2F, or CHF2 and
• R6 is optionally substituted C1-6 alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted C3-10 cycloalkyl,
• wherein said C1-6 alkyl is optionally substituted with one substituent selected from the group consisting of hydroxyl, C1-3 alkoxy and —ORa,
• wherein said aryl, heteroaryl, heterocyclic and C3-10 cycloalkyl are optionally substituted with one to three substituents each independently selected from the group consisting of:
• halo;
• hydroxyl;
• cyano;
• nitro;
• C1-4 alkoxy;
• C1-3 haloalkyl;
• C1-3 haloalkoxy;
• C1-6 alkyl;
• C3-6 cycloalkyl optionally substituted with one to three substituents each independently selected from the group consisting of:
• hydroxyl, cyano, C1-3 alkyl, C1-3 alkoxy, and C1-3 haloalkyl;
• phenyl optionally substituted with one to three substituents each independently selected from the group consisting of:
• halo, hydroxyl, cyano, nitro, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, C1-6 alkyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, phenoxy, —COORb, —SO2Rb, —NHC(O)Rb, and NRbRb;
• 5-6 membered heteroaryl optionally substituted with one to three substituents each independently selected from the group consisting of:
• halo, hydroxyl, cyano, C1-3 alkyl, C1-3 alkoxy;
• 5-6 membered heterocyclic optionally substituted with one to three substituents each independently selected from the group consisting of:
• halo, hydroxyl, oxo, NH2, and C1-3 alkyl;
• —CH2Ra;
• —ORa;
• —C(O)Ra;
• —NRaRb;
• —COORa;
• —SO2Ra;
• —SO2Rb;
• —NHC(O)Ra;
• —NHC(O)Rb;
• —C(O)NRaRb;
• —C(O)NHRb;
• and —SO2NRbRb;
• or
• R5b and R6 are joined together forming an optionally substituted C3-7 cycloalkyl group or an optionally substituted group of formula (a):
• wherein n is 1, 2, or 3 and
• said C3-7 cycloalkyl and group of formula (a) are optionally substituted with one to three substituents each independently selected from the group consisting of:
• halo, hydroxyl, cyano, nitro, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, C1-6 alkyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocyclic, benzyloxy, —COORb, —SO2Rb, —NHC(O)Rb, and —NRbRb;
• each Ra is independently optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted C3-7 cycloalkyl,
• wherein said phenyl and heteroaryl are optionally substituted with one to three substituents each independently selected from the group consisting of halo, hydroxyl, cyano, nitro, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, and C1-3 alkyl,
• wherein said heterocyclic is optionally substituted with one to three substituents each independently selected from the group consisting of halo, hydroxyl, oxo, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, C1-4 alkyl, C3-5 cycloalkyl, —C(O)Rb, and —NRbRb, and
• wherein said C3-7 cycloalkyl is optionally substituted with one to three substituents each independently selected from the group consisting of halo, hydroxyl, oxo, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, and C1-3 alkyl;
• and
• each Rb is independently hydrogen or C1-6 alkyl;
• or a pharmaceutically acceptable salt thereof.